Menu Back toEngaging-the-Rare-Disease-Community-to-Design-Clinical-Trials

DIA 2018 Global Annual Meeting


Engaging the Rare Disease Community to Design Clinical Trials

    Session Chair(s)
      Scott Douglas Schliebner, MPH

      Scott Douglas Schliebner, MPH

      • Vice President, Scientific Affairs, Rare Diseases
      • PRA Health Sciences, United States
    In this session, participants will hear several recent examples of how to best engage with different patient communities with respect to clinical trial design.
    Learning Objective : Participants will gain insight into the best practices for how and when to engage with the rare disease community. Participants will learn how patients and patient advocates can help with the drug development process and why their perspective is critical to drug development. Recent examples and "lessons learned" will be shared with the audience that they can apply within their own setting.
    Speaker(s)
      Scott Douglas Schliebner, MPH

      Nothing About Us, Without Us: Best Practices for Engaging With the Rare Disease Patient Community

      Scott Douglas Schliebner, MPH

      • Vice President, Scientific Affairs, Rare Diseases
      • PRA Health Sciences, United States
      Bruce  Wynne, PharmD

      Enrollment: Using Patient Advocacy Groups to Design a Better Trial, Find Participants, and Manage Studies in Rare Diseases

      Bruce Wynne, PharmD

      • Director, Clinical Operations Lead
      • CSL Behring, United States